Financial Analysis: Inogen (NASDAQ:INGN) & Pathfinder Cell Therapy (OTCMKTS:PFND)

Inogen (NASDAQ:INGN) and Pathfinder Cell Therapy (OTCMKTS:PFND) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership.

Profitability

This table compares Inogen and Pathfinder Cell Therapy’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inogen	-0.66%	0.21%	0.16%
Pathfinder Cell Therapy	N/A	N/A	N/A

Insider & Institutional Ownership

98.0% of Inogen shares are held by institutional investors. 4.8% of Inogen shares are held by insiders. Comparatively, 15.1% of Pathfinder Cell Therapy shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Inogen and Pathfinder Cell Therapy’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$361.94 million	2.85	$20.95 million	$1.07	43.55
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A

Inogen has higher revenue and earnings than Pathfinder Cell Therapy.

Volatility and Risk

Inogen has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Pathfinder Cell Therapy has a beta of -0.18, indicating that its share price is 118% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Inogen and Pathfinder Cell Therapy, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1	3	1	0	2.00
Pathfinder Cell Therapy	0	0	0	0	N/A

Inogen presently has a consensus price target of $53.75, indicating a potential upside of 15.34%. Given Inogen’s higher possible upside, research analysts plainly believe Inogen is more favorable than Pathfinder Cell Therapy.

Summary

Inogen beats Pathfinder Cell Therapy on 7 of the 9 factors compared between the two stocks.

Inogen Company Profile

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.

Pathfinder Cell Therapy Company Profile

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.